Ocular Therapeutix

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Our robust product pipeline positions Ocular Therapeutix to become a leader in the ophthalmic space due to our ability to create drug delivery solutions that reduce the complexity and burden of the current standard of care by developing sustained release alternatives. With a focus on advancing our products through to Phase 3 clinical trials, our intention is to develop a commercially viable portfolio to overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing for better patient outcomes.

Ocular Therapeutix’s first commercial drug product, DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. A supplemental new drug application for the treatment of ocular itching associated with allergic conjunctivitis for DEXTENZA has received a target action date under the Prescription Drug User Fee Act, commonly known as PDUFA, of October 18, 2021. Ocular Therapeutix’s earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Currently in phase 2 clinical trials, Ocular Therapeutix is currently evaluating each of OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix’s first commercialized product, ReSure® Sealant, is FDA-approved and indicated for intraoperative management of clear corneal incisions (up to 3.5mm) with a demonstrated wound leak for which a temporary dry surface can be achieved, in order to prevent postoperative fluid egress from such incisions following cataract surgery with intraocular lens (IOL) placement in adults.

Outside of the ophthalmic realm and behind the doors of our headquarters in Bedford, MA, we strive to build a strong culture where employees can flourish and achieve their career goals. We encourage out of the box thinking, cross-functional collaboration, and creativity.

Corporate Highlights

Transforming Current Standard of Care

With sustained-release therapies using our proprietary hydrogel platform

Developing Pipeline with Multi-Stage Product Candidates

Diversified across several therapeutic areas in ophthalmology

Protecting Innovation

Ocular products are protected by solid IP, technical know-how, and NDA regulatory applications that help preserve exclusivity for extended periods of time.

Evolving to Partnership Mindset

To maximize value of pipeline and enable new collaborations

Targeting Large Market Opportunities

With addressable market of $12B in the U.S.1-4*

REFERENCES: 1. 2019 Retina Pharma Market Scope Report. 2. 2019 Glaucoma Pharma Market Scope Report. 3. 2019 Dry Eye Market Scope Report. 4. Centers for Medicare & Medicaid Services. https://www.cms.gov/license/ama?file=files/zip/medicare-national-hcpcs-aggregate-cy2018.zip.

*These data reflect the total global market for the respective indications. Our market opportunity for such indications reflects a portion of this market.